Literature DB >> 10219579

Isolated renal Aspergillus abscess in an AIDS patient with a normal CD4+ cell count on highly active antiretroviral therapy.

D Rey1, E de Mautort, C Saussine, Y Hansmann, J Waller, R Herbrecht, D Christmann, V Lindner, V Letscher-Bru, H Koenig, J M Lang.   

Abstract

Isolated renal Aspergillus abscess is a very rare complication of HIV infection. It usually occurs in patients with severe immune deficiency. The case of a 29-year-old HIV-infected homosexual male, a nonintravenous drug abuser, who developed a right renal Aspergillus abscess despite normalization of the CD4+ cell count after highly active antiretroviral treatment is described. When antimicrobial treatment failed (amphotericin B followed by itraconazole), he was cured by right nephrectomy and remains in good health 3 months later with no recurrence. In cases of Aspergillus renal abscess in HIV-infected patients, surgery is the treatment of choice, especially in the current era of highly active antiretroviral therapy.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10219579     DOI: 10.1007/s100960050242

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  4 in total

1.  A renal aspergilloma--an unusual presentation of aspergillosis in an HIV patient.

Authors:  David Meya; Isaac Lwanga; Allan Ronald; Edward Kigonya
Journal:  Afr Health Sci       Date:  2005-12       Impact factor: 0.927

Review 2.  Urologic complications of HIV and AIDS.

Authors:  Chris F Heyns; Adam E Groeneveld; Nelson B Sigarroa
Journal:  Nat Clin Pract Urol       Date:  2009-01

3.  [Renal aspergilloma: retroperitoneoscopic resection as a minimally invasive organ preservation treatment option].

Authors:  C Wetterauer; M Rieken; G Müller; A Bachmann; G Bonkat
Journal:  Urologe A       Date:  2014-04       Impact factor: 0.639

4.  Rationale for an Association Between PD1 Checkpoint Inhibition and Therapeutic Vaccination Against HIV.

Authors:  Gilberto Filaci; Daniela Fenoglio; Lucia Taramasso; Francesco Indiveri; Antonio Di Biagio
Journal:  Front Immunol       Date:  2018-10-23       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.